Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and ...

EQS-News: Eckert & Ziegler SE / Key word (s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 ...

Classic car collectors will have a rare opportunity to bid on three exceptional vintage automobiles at the 6th Annual ...

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...